

H
H
I
H2
I

Serial No. 08/067,148
Atty. Docket No. 3495.0004-04

30. (Amended) [An] A purified immunological complex comprising a [purified] protein of human immunodeficiency virus type 1 (HIV-1) and an antibody against said protein, which antibody binds with said protein, wherein said protein is p18 protein of HIV.

Please add the following new claims:

--37. An antibody directed against HIV-1 p12 antigen, wherein said antibody is formed using an HIV-1 extract containing p12 or using purified HIV-1 p12 protein in animals.

38. An antibody directed against HIV-1 p18 antigen, wherein said antibody is formed using an HIV-1 extract containing p18 or using purified HIV-1 p18 protein in animals.

39. A mixture of antibodies directed against antigens present in an extract of HIV-1 virus; wherein said mixture of antibodies is formed using an HIV-1 extract or purified HIV-1 protein in animals; and wherein said antigens are selected from the group consisting of p12 and p25.

40. A mixture of antibodies directed against antigens present in an extract of HIV-1 virus; wherein said mixture of antibodies is formed using an HIV-1 extract or purified HIV-1 protein in animals; and wherein said antigens are selected from the group consisting of p18 and p25.

41. A mixture of antibodies directed against antigens present in an extract of HIV-1 virus; wherein said mixture of antibodies is formed using an HIV-1 extract or purified HIV-1

I
**Serial No. 08/067,148
Atty. Docket No. 3495.0004-04**

H2
protein in animals; and wherein said antigens are selected from the group consisting of p12, p18, p25, p15, p36, p42, and p80.

42. The antibody of any one of claims 37 or 38, wherein said antibody is monoclonal.
43. The mixture of antibodies of any one of claims 39-41, wherein said antibodies are monoclonal.
44. An antibody isolated from human serum, which binds with an antigen present in an extract of HIV-1 virus; wherein said antigen is selected from the group consisting of p12, p18, p25, p15, p36, p42, and p80.

REMARKS

Applicants respectfully request reconsideration of this application. Claims 15, 16, and 18-20 have been canceled. Claims 29 and 30 have been amended. Claims 37-44 are new. The amendments are fully supported by the specification, as indicated below. No new matter is added by the amendments.

Claims 15, 16, 18-20, and 29-31 were rejected under 35 U.S.C. § 112, first paragraph, for allegedly containing subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. The Examiner bases this rejection on an alleged inability of the disclosure to reasonably convey to the skilled artisan that applicants were in possession of the claimed antibodies and immune complexes. The Examiner